BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%

BIOCAUSE HEILEN PHARMA released its semi-annual report for 2025, with operating revenue of 235 million yuan, a year-on-year decrease of 2.93%; net profit attributable to the parent company was 18.5471 million yuan, a year-on-year decline of 72.92%. After deducting non-recurring gains and losses, the net profit was 4.4162 million yuan, a year-on-year decrease of 93.21%. The basic earnings per share were 0.06 yuan. The company plans to distribute 4.5 additional shares for every 10 shares to all shareholders and actively promote the implementation of fundraising investment projects, including the safety and environmental upgrade technical reform project for the hydrolysis and acidification position of ibuprofen raw materials and the construction of high-end pharmaceutical formulation internationalization projects